Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Volume 14 Issue 8, August 2015

'Immune checkpoints' by Susanne Harris, inspired by the Review on p561. Barriers from dashadima/iStock/Thinkstock

Comment

  • The treatment of tuberculosis is based on combinations of drugs that directly targetMycobacterium tuberculosis. A new global initiative is now focusing on a complementary approach of developing adjunct host-directed therapies.

    • Alimuddin Zumla
    • Jeremiah Chakaya
    • Markus Maeurer
    Comment

    Advertisement

Top of page ⤴

News and Analysis

Top of page ⤴

News in Brief

Top of page ⤴

Biobusiness Briefs

Top of page ⤴

An Audience With

  • Pierre Meulien, soon to be the new Executive Director of The Innovative Medicines Initiative, discusses his plans to move the European public-private partnership forward.

    An Audience With
Top of page ⤴

From the Analyst's Couch

  • This article discusses the opportunities and challenges in the application of financially adaptive clinical trials, which combine key aspects of adaptive trial design and financial analytics.

    • Frank S. David
    • Sarah Bobulsky
    • Nitin Patel
    From the Analyst's Couch
Top of page ⤴

Research Highlight

Top of page ⤴

In Brief

Top of page ⤴

Opinion

  • Incentives are increasingly available for the development of new drugs to tackle antibiotic resistance, but major scientific challenges remain, such as achieving penetration into bacteria. Tommasi and colleagues describe AstraZeneca's experiences in antibacterial drug discovery over the past decade using both target-based and phenotypic screening approaches, and discuss the reasons for failure as well as strategies to improve cytoplasmic penetration.

    • Ruben Tommasi
    • Dean G. Brown
    • Alita A. Miller
    Opinion
Top of page ⤴

Review Article

  • Solute carrier (SLC) transporters mediate a large number of physiological processes, and the dysfunction of individual transporters has been implicated in many Mendelian diseases. In this Review, Giacomini and colleagues summarize these roles and ways in which SLC transporters can be targeted by drugs, and highlight current and investigational drugs that modulate SLC transporters.

    • Lawrence Lin
    • Sook Wah Yee
    • Kathleen M. Giacomini
    Review Article
  • Anticancer immunotherapy through checkpoint blockade enables the patient to mount active antitumour responses and can dramatically improve survival. In this Review, Mahoney, Rennert and Freeman examine targets for next-generation immunomodulators and discuss how these may be integrated in rational combination therapies with existing and upcoming immune-targeted drugs.

    • Kathleen M. Mahoney
    • Paul D. Rennert
    • Gordon J. Freeman
    Review Article
Top of page ⤴

Correspondence

Top of page ⤴

Search

Quick links